These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 31896938)

  • 1. Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review.
    Pierrard J; Seront E
    Curr Oncol; 2019 Dec; 26(6):395-403. PubMed ID: 31896938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
    Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
    Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
    Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
    Hayase E; Jenq RR
    Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis.
    Abu-Sbeih H; Wang Y
    Dig Dis Sci; 2020 Mar; 65(3):797-799. PubMed ID: 32040664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
    Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
    Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
    Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
    Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between gut microbiota and immune checkpoint inhibitor-related colitis.
    Zhou G; Zhang N; Meng K; Pan F
    Front Immunol; 2022; 13():1001623. PubMed ID: 36389768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex interactions between the microbiome and cancer immune therapy.
    Schwartz DJ; Rebeck ON; Dantas G
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiome influencers of checkpoint blockade-associated toxicity.
    Wang Y; Jenq RR; Wargo JA; Watowich SS
    J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36622383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
    Kostine M; Mauric E; Tison A; Barnetche T; Barre A; Nikolski M; Rouxel L; Dutriaux C; Dousset L; Prey S; Beylot-Barry M; Seneschal J; Veillon R; Vergnenegre C; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Ravaud A; Forcade E; Schaeverbeke T;
    Eur J Cancer; 2021 Nov; 157():474-484. PubMed ID: 34649118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
    Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
    J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The intimate relationship between gut microbiota and cancer immunotherapy.
    Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
    Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
    Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiome for predicting immune checkpoint blockade-associated adverse events.
    Hu M; Lin X; Sun T; Shao X; Huang X; Du W; Guo M; Zhu X; Zhou Y; Tong T; Guo F; Han T; Wu X; Shi Y; Xiao X; Zhang Y; Hong J; Chen H
    Genome Med; 2024 Jan; 16(1):16. PubMed ID: 38243343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications.
    Guven DC; Aktas BY; Simsek C; Aksoy S
    Future Oncol; 2020 Mar; 16(9):497-506. PubMed ID: 32100550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
    Elkrief A; Derosa L; Kroemer G; Zitvogel L; Routy B
    Ann Oncol; 2019 Oct; 30(10):1572-1579. PubMed ID: 31268133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
    Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
    Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.